[{"id":"f52ea7ba-bfbd-4917-b198-17afffc30288","acronym":"","url":"https://clinicaltrials.gov/study/NCT05553834","created_at":"2022-09-23T17:07:20.162Z","updated_at":"2024-07-02T16:35:01.068Z","phase":"Phase 2","brief_title":"PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung","source_id_and_acronym":"NCT05553834","lead_sponsor":"Duke University","biomarkers":" EGFR • BRAF • MET • ROS1 • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Praluent (alirocumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2024-05-24"},{"id":"0cfe572f-7934-4703-b8bb-bebef2998a06","acronym":"","url":"https://clinicaltrials.gov/study/NCT04862260","created_at":"2021-04-27T14:52:42.546Z","updated_at":"2024-07-02T16:35:01.875Z","phase":"Phase 1","brief_title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT04862260","lead_sponsor":"CHU de Quebec-Universite Laval","biomarkers":" APOA1 • APOC3 • ANGPTL3 • ANGPTL8","pipe":"","alterations":" ","tags":["APOA1 • APOC3 • ANGPTL3 • ANGPTL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • atorvastatin • Repatha (evolocumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-22"},{"id":"eb45600d-a134-491a-b1b8-26b3e543335e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06421298","created_at":"2024-05-25T04:21:54.526Z","updated_at":"2024-07-02T16:35:02.560Z","phase":"Phase 2","brief_title":"A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.","source_id_and_acronym":"NCT06421298","lead_sponsor":"Jinghui Wang","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/17/2024","start_date":" 05/17/2024","primary_txt":" Primary completion: 05/30/2027","primary_completion_date":" 05/30/2027","study_txt":" Completion: 05/30/2027","study_completion_date":" 05/30/2027","last_update_posted":"2024-05-20"},{"id":"9dfa2a5f-d32b-4303-9563-ebf244f307ad","acronym":"TOP2101","url":"https://clinicaltrials.gov/study/NCT05144529","created_at":"2021-12-03T17:53:35.856Z","updated_at":"2024-07-02T16:35:48.347Z","phase":"Phase 2","brief_title":"A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC","source_id_and_acronym":"NCT05144529 - TOP2101","lead_sponsor":"Scott Antonia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Repatha (evolocumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-05-10"}]